NTSR1 and neoplasm: In this G5-CHC-R nanovaccine, the immunomodulator R848 is conjugated to G5 via a hypoxia-sensitive linker and can thus be cleaved by nitroreductase (NTR), which is highly expressed in tumor tissues, enabling the localized release of R848 at the tumor site.